Towards ultra-fast treatments: large energy acceptance beam delivery systems and opportunities for proton beam therapy - Summary - MDSpire

Towards ultra-fast treatments: large energy acceptance beam delivery systems and opportunities for proton beam therapy

  • By

  • Jacinta Yap

  • Adam Steinberg

  • Hannah Norman

  • Konrad P. Nesteruk

  • Suzie Sheehy

  • June 3, 2026

  • 0 min

Share

Objective:

To review advancements in proton beam therapy (PBT) focusing on enhancing treatment speed through high energy acceptance beam delivery systems.

Key Findings:
  • Proton beam therapy offers precise dose delivery capabilities.
  • The energy layer switching time (ELST) remains a significant limitation in current beam delivery systems.
  • Increasing the energy acceptance range can minimize ELST.
Interpretation:

Limitations:
  • Current technologies still face challenges in fully realizing the benefits of proton beam therapy.
  • High costs and limited access to PBT facilities hinder widespread adoption.
Conclusion:

Original Source(s)

Towards ultra-fast treatments: large energy acceptance beam delivery systems and opportunities for proton beam therapy

  • by Jacinta Yap, Adam Steinberg, Hannah Norman, Konrad P. Nesteruk, Suzie Sheehy

  • June 3, 2026

Related Content

RAS(ON) Inhibitor Doubles Median Overall Survival in Results of Phase 3 Trial for Patients with Metastatic Pancreatic Cancer

At the ASCO annual meeting, Dana-Farber’s Brian Wolpin, MD, MPH, presented positive results from the RASolute 302 trial showing a substantial prolongation of survival for patients with previously treated metastatic pancreatic cancer, regardless of RAS mutation status, taking daraxonrasib, an investigational oral RAS(ON) multi-selective inhibitor, compared with chemotherapy.

  • June 1, 2026

  • 5 min
LUCAT1 promotes stemness in head and neck squamous cell carcinoma by sponging miR-128

Perioperative Apalutamide in High-Risk Localized or Locally Advanced Prostate Cancer Reduces Risk of Metastasis and Death

High-risk localized and locally advanced prostate cancer patients treated with apalutamide — a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI) — plus hormone therapy before and after prostate cancer surgery resulted in more major pathologic responses and reduced the risk of metastasis or death, meeting both primary endpoints, in an international phase 3 clinical trial led by principal investigator Mary-Ellen Taplin, MD, medical oncologist at Dana-Farber Cancer Institute, and Adam Kibel, MD, chair of the Department of Urology at Mass General Brigham.

  • June 1, 2026

  • 4 min